Journey Medical Corp: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 10, 2023 and accepted by EDGAR at Aug 10, 2023, 16:45 ET.
Management's discussion and analysis
As filed, 41,068 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Certain matters discussed in this report may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “should,” “intend” and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in or implied by these forward-looking statements due to a variety of factors, including, without limitation:
- the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized;
- a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income;
- we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations;
- our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results;
- competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products;
- the risk that our products do not achieve broad market acceptance, including by government and third-party payors;
- our reliance third parties for several aspects of our operations;
- our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful;
- the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29 product candidate and any future product candidates that we may develop, in-license or acquire;
- clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates;
- our competitors could develop and commercialize products similar or identical to ours;
- risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products;
- our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity;
- the substantial doubt expressed about our ability to continue as a going concern;
- the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials;
- our potential need to raise additional capital;
- Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders;
- and the risks described in under the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”).
The forward-looking statements contained in this report reflect our views and assumptions as of the effective date of this report. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. Except as required by law, we assume no responsibility for updating any forward-looking statements.
We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Overview
We are a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are actively marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life and physicians and other licensed medical professionals to provide better care for their patients. We aim to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through our field sales force.
Critical Accounting Polices and Uses of Estimates
Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of revenues, expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
For a discussion of our critical accounting estimates, see the section of the 2022 Form 10-K titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Use of Estimates.” There were no material changes in our critical accounting estimates or accounting policies from December 31, 2022.
Accounting Pronouncements
During the six-month period ended June 30, 2023, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2022 Form 10-K that are expected to materially affect the Company’s present or future financial statements.
Emerging Growth Company and Smaller Reporting Company Status
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in our annual reports on Form 10-K, an exemption from the requirement to provide an auditor’s report on internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
We are also a “smaller reporting company,” meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, have reduced disclosure obligations regarding executive compensation, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 to our consolidated financial statements in this report on Form 10-Q.
Results of Operations
The following table summarizes our results of operations for the three-month periods ended June 30, 2023 and 2022:
Comparison of the Three-Month Periods Ended June 30, 2023 and 2022
($ in thousands, except per share data)
| Revenue: | | Three-Month Periods Ended June 30, 2023 | | 2022 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $16,961 | $18,235 | | $(1,274) | | -7% | ||
| Other revenue | | 211 | | 56 | | 155 | | 277% |
| Total revenue | | 17,172 | | 18,291 | | (1,119) | | -6% |
| | | | | | | | | |
| Operating expenses | | | | | | | ||
| Cost of goods sold - product revenue | 7,767 | 7,633 | | 134 | | 2% | ||
| Research and development | 1,774 | 2,609 | | (835) | | -32% | ||
| Selling, general and administrative | 12,141 | 15,191 | | (3,050) | | -20% | ||
| Loss on impairment of intangible assets | | 3,143 | | — | | 3,143 | | 100% |
| Total operating expenses | 24,825 | 25,433 | | (608) | | -2% | ||
| Loss from operations | (7,653) | (7,142) | | (511) | | 7% | ||
| | | | | | | | | |
| Other expense (income) | | | | | | | ||
| Interest income | (79) | (4) | | (75) | | 1875% | ||
| Interest expense | | 756 | | 454 | | 302 | | 67% |
| Foreign exchange transaction losses | | 33 | | — | | 33 | | 100% |
| Total other expense (income) | 710 | 450 | | 260 | | 58% | ||
| Loss before income taxes | (8,363) | (7,592) | | (771) | | 10% | ||
| | | | | | | | | |
| Income tax benefit | — | (64) | | 64 | | -100% | ||
| Net Loss | | $(8,363) | | $(7,528) | | $(835) | | 11% |
Revenues
The following table reflects our net product revenue for the three-month periods ended June 30, 2023 and 2022:
($ in thousands)
| | | Three-Month Periods Ended June 30, 2023 | | 2022 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Qbrexza® | | $8,079 | | $6,111 | | $1,968 | | 32% |
| Accutane® | | 5,579 | | 5,200 | | 379 | | 7% |
| Amzeeq® | | 1,374 | | 1,265 | | 109 | | 9% |
| Zilxi® | | 572 | | 555 | | 17 | | 3% |
| Targadox® | | 664 | | 2,756 | | (2,092) | | -76% |
| Exelderm® | | 538 | | 1,313 | | (775) | | -59% |
| Ximino® | | 155 | | 1,035 | | (880) | | -85% |
| Total net product revenue | | $16,961 | | $18,235 | | $(1,274) | | -7% |
Total net product revenues decreased by $1.3 million, or 7.0%, to $17.0 million for the three-month period ended June 30, 2023, from $18.2 million for the three-month period ended June 30, 2022. The decrease is primarily due to lower unit volumes from our legacy products, Targadox, Ximino and Exelderm, substantially driven by continued generic competition for Targadox. The decrease was offset by an increase in net product revenues from our four core products, Qbrexza, Accutane, Amzeeq and Zilxi due to increased unit volumes as a result of our focused sales and marketing emphasis on these products. Qbrexza, Accutane, Amzeeq and Zilxi, all acquired and launched since 2021, reflect approximately 92%, or $15.6 million, of our total net product revenue for the three-month period ended June 30, 2023.
Other revenue
($ in thousands)
| | | Three-Month Periods Ended June 30, 2023 | | 2022 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Other revenue | | $211 | | $56 | | $155 | | 277% |
| Total other revenue | | $211 | | $56 | | $155 | | 277% |
Other revenues increased approximately $155,000, to $211,000 for the three-month period ended June 30, 2023, from $56,000 for the three-month period ended June 30, 2022. Other revenue reflects royalties on sales of Rapifort® Wipes 2.5%. in Japan for the treatment of primary axillary hyperhidrosis (the Japanese equivalent to U.S. FDA approved Qbrexza®), from Maruho, our exclusive out-licensing partner in Japan. Manufacturing and marketing approval for this product was obtained in February 2022.
Gross-to-Net Sales Accruals
We record gross-to-net sales accruals for chargebacks, distributor service fees, prompt pay discounts, sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.
Gross-to-net sales accruals and the balance in the related allowance accounts for the three-month periods ended June 30, 2023 and 2022, were as follows:
($’s in thousands)
| | | Chargebacks and other allowances | | Distributor Service Fees | | Prompt Pay Discounts | | Returns | | Coupons | | Managed Care Rebates | | Gov’t Rebates | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of March 31, 2023 | | $222 | | $753 | | $175 | | $3,371 | | $2,217 | | $3,691 | | $1,168 | | $11,597 |
| Current provision related to sales in the current period | | 748 | | 1,512 | | 293 | | 2,082 | | 25,764 | | 5,842 | | 2,678 | | 38,919 |
| Checks/credits issued to third parties | | (705) | | (1,386) | | (276) | | (908) | | (30,056) | | (5,801) | | (429) | | (39,561) |
| Reclass coupon vendor deposit to accounts payable | | — | | — | | — | | — | | 6,167 | | — | | — | | 6,167 |
| Balance as of June 30, 2023 | | $265 | | $879 | | $192 | | $4,545 | | $4,092 | | $3,732 | | $3,417 | | $17,122 |
($’s in thousands)
| | | Chargebacks and other allowances | | Distributor Service Fees | | Prompt Pay Discounts | | Returns | | Coupons | | Managed Care Rebates | | Gov’t Rebates | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of March 31, 2022 | | $343 | | $818 | | $225 | | $3,151 | | $6,660 | | $2,635 | | $1,026 | | $14,858 |
| Current provision related to sales in the current period | | 574 | | 1,456 | | 274 | | 1,170 | | 30,912 | | 6,543 | | 752 | | 41,681 |
| Checks/credits issued to third parties | | (644) | | (1,341) | | (305) | | (1,594) | | (35,073) | | (5,987) | | (560) | | (45,504) |
| Balance as of June 30, 2022 | | $273 | | $933 | | $194 | | $2,727 | | $2,499 | | $3,191 | | $1,218 | | $11,035 |
Our provision for gross-to-net allowances was $17.1 million at June 30, 2023, compared to $11.6 million at March 31, 2023. The increase is mainly due to the reclassification of certain coupon deposits to accounts payable as the related coupon accrual for these coupons has decreased while we continue to have accounts payables to the vendor for these processed coupons.
During the second quarter we implemented an additional coupon processing access program for our specialty pharmaceutical customers (direct customers) whereby upon prescription fulfillment and application of a coupon we would provide a credit to the direct customer which is reflected as reduction of the accounts receivable as they will deduct the credit against sales invoices remitted to us. Previously for these customers the coupons were processed and funded by a coupon vendor which we reimbursed for funded coupons. The change in coupon vendor did not impact the classification of the coupon provision in the Company’s condensed consolidated statements of operations. We continue to estimate coupon cost at the time of sale.
Cost of Goods Sold
Cost of goods sold increased by $0.2 million, or 2%, to $7.8 million for the three-month period ended June 30, 2023, from $7.6 million for the three-month period ended June 30, 2022. The increase is predominantly a result of increases to our inventory reserves of $0.5 million primarily related to expired finished goods, raw material inventory, and inventory estimated to be in excess of anticipated usage. Additionally, prescription drug user fee and product license amortization increased by $0.2 million and $0.1 million, respectively, from the three-month period ended June 30, 2022. These increases are partially offset by an $0.8 million decrease in product royalties driven by a decrease in Targadox® royalties as a result of decreased sales from generic competition and Qbrexza royalties resulting from a contractual decrease in the Qbrexza royalty percentage from the prior-year quarter. In addition, the three-month period ended June 30, 2022 included an inventory step-up of $0.2 million for inventory units sold related to the acquired finished goods for Ameeq® and Zilxi® from Vyne in January 2022.
Research and Development
Research and Development expense decreased by $0.8 million, or 32%, to $1.8 million for the three-month period ended June 30, 2023, from $2.6 million for the three-month period ended June 30, 2022. The decrease is related to lower clinical trial expenses to develop our DFD-29 product as the project winds down. On July 11, 2023 we announced positive topline results from our two phase 3 clinical trials marking the commencement of the trials.
Selling, General and Administrative
Selling, general and administrative (“SG&A”) expenses decreased by $3.0 million, or 20%, to $12.1 million for the three-month period ended June 30, 2023, from $15.2 million for the three-month period ended June 30, 2022. The decrease is mainly due to our expense reduction efforts primarily in sales and marketing and other SG&A areas. During the last quarter of 2022, we implemented a cost reduction initiative designed to improve operational efficiencies, optimize expenses and reduce overall costs. The initiative is intended to reduce selling, general, and administrative expenses to better align costs with their revenue-generating capabilities. In connection with the cost reduction initiative, during the three-month period ended June 30, 2023, we executed a headcount reduction to our salesforce and implemented marketing and other cost cuts.
Loss on impairment of intangible assets
We recorded a loss on the impairment of intangible assets of $3.1 million for the three-month period ended June 30, 2023 related to the impairment of the Ximino intangible asset. During the six-month period ended June 30, 2023, we experienced lower net product revenues and gross profit levels for the Ximino products.
Interest Expense
Interest expense increased by $0.3 million to $0.8 million for the three-month period ended June 30, 2023, from $0.5 million for the three-month period ended June 30, 2022. The increase is primarily attributable to cash interest paid under the EWB Facility term loan as a result of interest rate increases during 2022 and 2023.
Comparison of the Six-Month Periods Ended June 30, 2023 and 2022
($in thousands, except per share data)
| Revenue: | | Six-Month Periods Ended June 30, 2023 | | 2022 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Product revenue, net | | $29,126 | | $39,031 | | $(9,905) | | -25% |
| Other revenue | | 259 | | 2,556 | | (2,297) | | -90% |
| Total revenue | | 29,385 | | 41,587 | | (12,202) | | -29% |
| | | | | | | | | |
| Operating expenses | | | | | | |||
| Cost of goods sold – product revenue | | 14,216 | | 15,836 | | (1,620) | | -10% |
| Research and development | | 3,807 | | 3,875 | | (68) | | -2% |
| Selling, general and administrative | | 25,433 | | 29,906 | | (4,473) | | -15% |
| Loss on impairment of intangible assets | | 3,143 | | — | | 3,143 | | 100% |
| Total operating expenses | | 46,599 | | 49,617 | | (3,018) | | -6% |
| Loss from operations | | (17,214) | | (8,030) | | (9,184) | | 114% |
| | | | | | | | | |
| Other expense (income) | | | | | | |||
| Interest income | | (201) | | (7) | | (194) | | 2771% |
| Interest expense | | 1,406 | | 843 | | 563 | | 67% |
| Foreign exchange transaction losses | | 80 | | — | | 80 | | 100% |
| Total other expense (income) | | 1,285 | | 836 | | 449 | | 54% |
| Loss before income taxes | | (18,499) | | (8,866) | | (9,633) | | 109% |
| | | | | | | | | |
| Income tax expense | | — | | 40 | | (40) | | -100% |
| Net Loss | | $(18,499) | | $(8,906) | | $(9,593) | | 108% |
Revenues
The following table reflects our net product revenue for the six-month periods ended June 30, 2023 and 2022:
($in thousands)
| | | Six-Month Periods Ended June 30, 2023 | | 2022 | | Change $% | | |
|---|---|---|---|---|---|---|---|---|
| Qbrexza® | | $12,173 | | $13,487 | | $(1,314) | | -10% |
| Accutane® | | 10,227 | | 10,107 | | 120 | | 1% |
| Amzeeq® | | 2,568 | | 4,731 | | (2,163) | | -46% |
| Zilxi® | | 886 | | 1,297 | | (411) | | -32% |
| Targadox® | | 1,457 | | 5,390 | | (3,933) | | -73% |
| Exelderm® | | 1,049 | | 2,017 | | (968) | | -48% |
| Ximino® | | 766 | | 2,002 | | (1,236) | | -62% |
| Total net product revenue | | $29,126 | | $39,031 | | $(9,905) | | -25% |
Total net product revenues decreased by $9.9 million, or 25.0%, to $29.1 million for the six-month period ended June 30, 2023, from $39.0 million for the six-month period ended June 30, 2022. The decrease is primarily due to lower unit volumes from our legacy products, Targadox, Ximino and Exelderm, substantially driven by continued generic competition for Targadox. In addition, the six-month period ended June 30, 2023 was negatively impacted by higher gross-to-net allowances for coupon rebates as a result of higher deductible rate resets, which occur at the beginning of each year, higher managed care rebates due to higher managed care program costs, higher product returns from higher-than-anticipated returns from the Dermira product lots purchased in 2021, and higher government rebates from increases in state rebate programs.
Other revenue
($in thousands)
| | | Six-Month Periods Ended June 30, 2023 | 2022 | Change $% | | |
|---|---|---|---|---|---|---|
| Other revenue | | $259 | $2,556 | $(2,297) | | -90% |
| Total other revenue | | $259 | $2,556 | $(2,297) | | -90% |
Other revenues decreased approximately $2.3 million, to $0.3 million for the six-month period ended June 30, 2023, from $2.6 million for the six-month period ended June 30, 2022. Other revenue reflects royalties on sales of Rapifort® Wipes 2.5% in Japan, from Maruho, the Company’s exclusive out-licensing partner in Japan. Other revenue for the six-month period ended June 30, 2022 includes a net $2.5 million milestone payment from Maruho. In January 2022, Maruho received manufacturing and marketing approval in Japan for Rapifort® Wipes 2.5% (Japanese equivalent to U.S. FDA approved QBREXZA®), for the treatment of primary axillary hyperhidrosis, triggering the one-time net payment.
Gross-to-Net Sales Accruals
We record gross-to-net sales accruals for chargebacks, distributor service fees, prompt pay discounts, sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.
Gross-to-net sales accruals and the balance in the related allowance accounts for the six-month period ended June 30, 2023 and 2022, were as follows:
($'s in thousands)
| | | Chargebacks and other allowances | | Distributor Service Fees | | Prompt Pay Discounts | | Returns | | Coupons | | Managed Care Rebates | | Gov't Rebates | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of December 31, 2022 | | $253 | | $929 | | $207 | | $3,689 | | $1,696 | | $3,594 | | $1,010 | | $11,378 |
| Current provision related to sales in the current period | | 1,371 | | 2,898 | | 548 | | 4,173 | | 53,694 | | 11,414 | | 4,341 | | 78,439 |
| Checks/credits issued to third parties | | (1,359) | | (2,948) | | (563) | | (3,317) | | (57,465) | | (11,276) | | (1,934) | | (78,862) |
| Reclass coupon vendor deposit to accounts payable | | — | | — | | — | | — | | 6,167 | | — | | — | | 6,167 |
| Balance as of June 30, 2023 | | $265 | | $879 | | $192 | | $4,545 | | $4,092 | | $3,732 | | $3,417 | | $17,122 |
($'s in thousands)
| | | Chargebacks and other allowances | | Distributor Service Fees | | Prompt Pay Discounts | | Returns | | Coupons | | Managed Care Rebates | | Gov't Rebates | | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance as of December 31, 2021 | | $622 | | $791 | | $197 | | $3,240 | | $4,992 | | $3,492 | | $690 | | $14,024 |
| Current provision related to sales in the current period | | 1,111 | | 2,852 | | 526 | | 2,290 | | 66,529 | | 10,234 | | 1,756 | | 85,298 |
| Checks/credits issued to third parties | | (1,460) | | (2,710) | | (529) | | (2,803) | | (69,022) | | (10,535) | | (1,228) | | (88,287) |
| Balance as of June 30, 2022 | | $273 | | $933 | | $194 | | $2,727 | | $2,499 | | $3,191 | | $1,218 | | $11,035 |
Our provision for gross-to-net allowances was $17.1 million at June 30, 2023, compared to $11.4 million at December 31, 2022. The increase is mainly due to the reclassification of certain coupon deposits to accounts payable as the related coupon accrual for these coupons has decreased while we continue to have accounts payables to the vender for these processed coupons.
During the second quarter we implemented an additional coupon processing access program for our specialty pharmaceutical customers (direct customers) whereby upon prescription fulfillment and application of a coupon we would provide a credit to the direct customer which is reflected as reduction of the accounts receivable as they will deduct the credit against sales invoices remitted to us. Previously for these customers the coupons were processed and funded by a coupon vendor which we reimbursed for funded coupons. The change in coupon vendor did not impact the classification of the coupon provision in the Company’s condensed consolidated statements of operations. We continue to estimate coupon cost at the time of sale.
Cost of Goods Sold
Cost of goods sold decreased by $1.6 million, or 10%, to $14.2 million for the six-month period ended June 30, 2023, from $15.8 million for the six-month period ended June 30, 2022. The decrease is mainly due to lower than-prior-year product royalties of $2.9 million driven by lower sales, and a substantial contractual decrease in the Qbrexza royalty percentage from the prior year period. In addition, the six-month period ended June 30, 2022 included an inventory step-up of $0.3 million for inventory units sold related to the acquired finished goods for Ameeq® and Zilxi® from Vyne in January 2022. These decreases are offset by higher cost of goods driven by higher than-prior-year inventory reserves of $0.5 million primarily related to expired finished goods, raw material inventory, and inventory estimated to be in excess of anticipated usage. Additionally, prescription drug user fee and product license amortization increased by $0.5 million and $0.1 million, respectively, from the six-month period ended June 30, 2022.
Research and Development
Research and Development expense decreased by $0.1 million, or 2%, to $3.8 million for the six-month period ended June 30, 2023, from $3.9 million for the six-month period ended June 30, 2022. The decrease is related to lower clinical trial expenses to develop our DFD-29 product as the project winds down. On July 11, 2023 we announced positive topline results from our two phase 3 clinical trials marking the commencement of the trials.
Selling, General and Administrative
Selling, general and administrative expenses decreased by $4.5 million, or 15%, to $25.4 million for the six-month period ended June 30, 2023, from $29.9 million for the six-month period ended June 30, 2022. The decrease is mainly due to our expense reduction efforts primarily in sales and marketing and other SG&A areas. During the last quarter of 2022, we implemented a cost reduction initiative designed to improve operational efficiencies, optimize expenses and reduce overall costs. The initiative is intended to reduce selling, general, and administrative expenses to better align costs with their revenue-generating capabilities. In connection with the cost reduction initiative, during the six-month period ended June 30, 2023, we executed a headcount reduction to our salesforce and implemented marketing and other cost cuts.
Loss on impairment of intangible assets
We recorded a loss on the impairment of intangible assets of $3.1 million for the six-month period ended June 30, 2023 related to the impairment of the Ximino intangible asset. During the six-month period ended June 30, 2023, we experienced lower net product revenues and gross profit levels for the Ximino products.
Interest Expense
Interest expense increased by $0.6 million to $1.4 million for the six-month period ended June 30, 2023, from $0.8 million for the six-month period ended June 30, 2022. The increase is primarily attributable to cash interest paid under the EWB Facility term loan as a result of interest rate increases during 2022 and 2023.
Liquidity and Capital Resources
At June 30, 2023, we had $8.2 million in cash and cash equivalents as compared to $32.0 million of cash and cash equivalents at December 31, 2022. Additionally at June 30, 2023, the Company has $8.75 million of restricted cash. In July 2023 we utilized the restricted cash of $8.75 million and $1.25 million of cash to fully repay the EWB Facility.
On December 30, 2022, we filed a shelf registration statement on Form S-3 (File No. 333-269079), which was declared effective by the Securities and Exchange Commission (“SEC”) on January 26, 2023. This shelf registration statement covers the offering, issuance, and sale by us of up to an aggregate of $150.0 million of our common stock, preferred stock, debt securities, warrants, and units (the “2022 Shelf”). At June 30, 2023, $150.0 million remains available under the 2022 Shelf. In connection with the 2022 shelf, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”), relating to shares of our common stock. In accordance with the terms of the Sales Agreement, we may offer and sell up to 4,900,000 shares of our common stock, par value $0.0001 per share, from time to time through or to B. Riley acting as our agent or principal. As of June 30, 2023, no shares have been issued under the 2022 Shelf.
As a result of increased losses in the latter part of 2022, during the last quarter of 2022, we implemented a cost reduction initiative designed to improve operational efficiencies, optimize expenses and reduce overall costs. The initiative is intended to reduce selling, general, and administrative expenses to better align costs with their revenue-generating capabilities. In connection with the cost reduction initiative, during the six-month period ended June 30, 2023, we executed a headcount reduction to our salesforce and implemented marketing and other cost cuts. The impact of the cost reduction initiatives is expected to result in a reduction of greater than $12.0 million of annual selling, general, and administrative costs.
We may seek a new borrowing relationship now that the EWB Facility has been terminated to provide additional working capital, and/or may seek to raise capital through additional debt or equity financing. We cannot make any assurances that such additional financing will be available to us and, if available, the terms may negatively impact our business and operations. As such, substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months from the date of issuance of the financial statements included in this Quarterly Report on Form 10-Q.
Cash Flows for the Six-Month Periods Ended June 30, 2023 and 2022
($’s in thousands)
| | | Six-Month Periods Ended June 30, 2023 | | 2022 | | Increase (Decrease) |
|---|---|---|---|---|---|---|
| Net cash provided by (used in) operating activities | | $3,013 | | $(2,416) | | $5,429 |
| Net cash used in investing activities | | (5,000) | | (20,000) | | 15,000 |
| Net cash provided by (used in) financing activities | | (13,036) | | 11,477 | | (24,513) |
| Net change in cash and cash equivalents | | $(15,023) | | $(10,939) | | $(4,084) |
Operating Activities
Net cash flows provided by operating activities for the six-month period ended June 30, 2023 increased by $5.4 million to $3.0 million from net cash flows used by operating activities of $2.4 million for the six-month period ended June 30, 2022. The increase was driven primarily by the non-cash intangible asset impairment of $3.1 million, as well an increase in cash inflows associated with the net changes in operating assets and liabilities of $11.2 million primarily attributable to accounts receivable, inventory, and accrued expensed. This was offset by an increase in the net loss of $9.6 million.
Investing Activities
Net cash used in investing activities decreased by $15.0 million from period-to-period. The six-month period ended June 30, 2023 reflects the $5.0 million deferred cash payment paid in January 2023 related to the VYNE Product Acquisition. The six-month period ended June 30, 2022 reflects the upfront $20.0 million payment for the VYNE Product Acquisition.
Financing Activities
Net cash flows used in financing activities for six-month period ended June 30, 2023 increased by $24.5 million to $13.0 million from $11.5 million of cash flows provided by financing activities for the six-month period ended June 30, 2022. The increase reflects a cash outflow of $10.0 million for the repayment of principal on the EWB term loan and net cash outflows of $2.9 million from the EWB revolving line of credit. Net cash provided by financing activities for the six-month period ended June 30, 2022 reflects net proceeds of $14.8 million from the EWB term loan offset by $2.0 million in payments of the installment notes related to our previously acquired products and $0.8 million for repayment our EWB revolving line of credit. Net cash provided by financing activities for the six-month period ended June 30, 2022 also reflects approximately $0.6 million in payments for debt issue and offering costs associated with our previously outstanding convertible preferred stock and our initial public offering of securities, which closed in November 2021.
Material Cash Requirements
In the normal course of business, we enter into contractual obligations that contain cash requirements of which the most significant to date include the following:
- As of June 30, 2023, we were required to make payments under the EWB Facility. In July 2023, we voluntarily repaid the entire $10.0 million outstanding term loan principal balance. The repayment satisfied all of the Company’s outstanding debt obligations under the EWB Facility. We therefore have no further obligations to EWB.
- Pursuant to our January 2022 agreement with VYNE Therapeutics, Inc. under which acquired Amzeeq® and Zilxi® (the “VYNE Product Acquisition Agreement”), upon the achievement of net sales milestone payments with respect to the products purchased in the VYNE Product Acquisition Agreement, we are also required to pay contingent consideration consisting of a one-time payment, per product, of $10 million, $20 million, $30 million, $40 million and $50 million upon each product reaching annual sales of $100 million, $200 million, $300 million, $400 million and $500 million, respectively. Each required payment must only be paid one time following the first achievement of the applicable annual sales milestone amount.
- On June 29, 2021, we entered into a license, collaboration, and assignment agreement (the “DFD-29 Agreement”) to obtain the global rights for the development and commercialization of a late-stage development modified release oral minocycline for the treatment of rosacea (“DFD-29”) with Dr. Reddy’s Laboratories, Ltd (“DRL”). Based on the development and commercialization of DFD-29, additional contingent regulatory and commercial milestone payments totaling up to $158.0 million may also become payable. Royalties ranging from ten percent to twenty percent are payable on net sales of the product. Additionally, the Company was required to fund and oversee the Phase 3 clinical trials beginning upon the license of DFD-29 in 2021. The Phase 3 clinical trials substantially concluded in July 2023 upon the receipt of positive topline results from the trials. The Company expects to pay an approximately $3.2 million filing fee in the fourth quarter to the FDA upon filing of DFD-29.
- We are contractually obligated to make installment milestone payments on our acquired licenses as follow:
($’s in thousands)
| Product | | Payments by Period Total | | 2023 | | 2024 |
|---|---|---|---|---|---|---|
| Ximino | | $3,000 | | $1,500 | | $1,500 |
| Accutane | | 1,000 | | 1,000 | | — |
| Total | | $4,000 | | $2,500 | | $1,500 |
- We are contractually obligated to make sales-based royalty payments to Dermira (for Qbrexza), Sun Pharmaceutical Industries (for Exelderm and Ximino) and PuraCap Caribe (for Targadox). Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted.
Market risk
As filed, 163 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.
Controls and procedures
As filed, 1,317 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of June 30, 2023, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations, which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.
Risk factors
As filed, 4,512 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We have disclosed below, as well as under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”), supplemented by the disclosure below, a number of risks which may materially affect our business, financial condition or results of operations. You should carefully consider these Risk Factors and other information set forth elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us may also materially adversely affect our business, financial condition and/or results of operations.
There is substantial doubt regarding our ability to continue as a going concern. We may need to raise additional funding (which may not be available on acceptable terms to the Company, or at all) and/or to delay, limit or terminate certain of our product development and commercialization efforts or other operations.
Based on our current business plan and the current amount of cash and cash equivalents available to us, we have concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of the financial statements included in our Quarterly Report on Form 10-Q for the period ended June 30, 2023. In May 2023, we paid the remaining balance on our revolving line of credit in the amount of $3.0 million and, in connection with an amendment to our credit facility with East West Bank, prepaid $10.0 million of our term loan under that facility. The $10.0 million remaining balance on the term loan was to be due July 1, 2024 and would have provided $1.25 million of working capital through August 31, 2023. In July 2023, we repaid the term loan in full, and therefore our assets are now unencumbered and available to support a new borrowing relationship to provide additional working capital, which we plan to pursue along with our costs reduction initiatives in 2023. In addition to reductions in sales force and marketing expenses, we may also seek to raise capital through additional debt or equity financing, which may include sales of securities under our existing shelf registration statement on Form S-3, including under the Sales Agreement with B. Riley, or under a new registration statement.
Our efforts to raise additional funding may divert our management from its day-to-day activities, which may adversely affect our ability to develop and commercialize our products. In addition, we cannot guarantee that financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. Potential indebtedness, if incurred, would result in increased fixed payment obligations, and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We may be required to relinquish rights to some of our technologies or products or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.
If funding for our operations is not available or not available on terms acceptable to us, our strategic plans may be limited. In addition, in order to address our current funding constraints, we may be required to further revise our business plan and strategy, which may result in us (i) significantly curtailing, delaying or discontinuing our DFD-29 research or development programs or the commercialization of any other products, (ii) selling certain of our assets and/or (iii) being unable to expand our operations or otherwise capitalize on our business opportunities. Such actions measures may become necessary whether or not we are able to raise additional capital. As a result, our business, financial condition, and results of operations could be materially affected.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $17.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $29.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $7.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $14.2m | us-gaap:CostOfRevenue |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-01-01 to 2023-06-30 | $3.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $12.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-01-01 to 2023-06-30 | $25.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$7.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$17.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $756.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $1.4m | us-gaap:InterestExpense |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$8.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$18.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$0.46 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-01-01 to 2023-06-30 | −$1.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$0.46 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-01-01 to 2023-06-30 | −$1.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 18,005,055 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-01-01 to 2023-06-30 | 17,906,671 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | $3.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $5.0m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2023-06-30 | $8.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $47.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $69.7m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $68.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $69.7m | us-gaap:Liabilities |
| Long-term debt | At period end2023-06-30 | $9.9m | us-gaap:LongTermDebt |
| Current portion of debt | At period end2023-06-30 | $9.9m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-06-30 | $5.0k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001410578-23-001702. Last ingested by Listed: Nov 13, 2026, 16:22 ET. Listed shows no prices and gives no investment advice.